The classical and non-classical axes of renin-angiotensin system in Parkinson disease: The bright and dark side of the moon.

Autor: Al-Kuraishy HM; Department of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Al-Hamash SM; Department of Pediatric Cardiology, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Jabir MS; Department of Applied science, University of technology, Iraq. Electronic address: alikadhim@uomustansiriyah.edu.iq., Al-Gareeb AI; Department of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Albuhadily AK; Department of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Albukhaty S; Department of Chemistry, College of Science, University of Misan, Maysan 62001, Iraq., Sulaiman GM; Department of Applied science, University of technology, Iraq.
Jazyk: angličtina
Zdroj: Ageing research reviews [Ageing Res Rev] 2024 Feb; Vol. 94, pp. 102200. Date of Electronic Publication: 2024 Jan 17.
DOI: 10.1016/j.arr.2024.102200
Abstrakt: Parkinson disease (PD) is a common brain neurodegenerative disease due to progressive degeneration of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). Of note, the cardio-metabolic disorders such as hypertension are adversely affect PD neuropathology through exaggeration of renin-angiotensin system (RAS). The RAS affects the stability of dopaminergic neurons in the SNpc, and exaggeration of angiotensin II (AngII) is implicated in the development and progression of PD. RAS has two axes classical including angiotensin converting enzyme (ACE)/AngII/AT1R, and the non-classical axis which include ACE2/Ang1-7/Mas receptor, AngIII, AngIV, AT2R, and AT4R. It has been shown that brain RAS is differs from that of systemic RAS that produce specific neuronal effects. As well, there is an association between brain RAS and PD. Therefore, this review aims to revise from published articles the role of brain RAS in the pathogenesis of PD focusing on the non-classical pathway, and how targeting of this axis can modulate PD neuropathology.
Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interest.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: